Osteogenesis Imperfecta Clinical Trial
— MOVE-OIOfficial title:
Evaluation of the Benefits of Adaptive Physical Activity in Children and Adolescents With Osteogenesis Imperfecta
Verified date | January 2023 |
Source | Hospices Civils de Lyon |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Osteogenesis imperfecta (OI) is a rare genetic disorder of increased bone fragility and low bone mass. It is conceivable that children and adolescents with OI are less active than healthy peers because of frequent fractures, immobilization,functionals limitations and no adapted physicals activity(APA). The hypothesis is that an Adapted physique activity could improve access of activity for patients with Osteogenesis Imperfecta (OI). The aim of the study is to evaluate benefice of APA,improve aerobic capacity, cardiovascular and bone benefits, and gain of quality of life. Children with OI between 6 and 18 years old will have a program of supervised "adapted training program" during one year. The program is adapted at each individual and without risk for the patient.
Status | Completed |
Enrollment | 30 |
Est. completion date | October 14, 2022 |
Est. primary completion date | October 14, 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 6 Years to 17 Years |
Eligibility | Inclusion Criteria: - Child with osteogenesis imperfecta - Child followed in the Reference centre for constitutional bone diseases in the Hôpital Femme Mère Enfant - Parent (s) / legal guardian who has been informed of the study and has accepted participation in the study by signing the consent. - Patient benefiting from a social security scheme Exclusion Criteria: - Medical and surgical contraindications to adapted physical activity. |
Country | Name | City | State |
---|---|---|---|
France | Centre de Référence des Maladies Rénales Rares - Hospices Civils de Lyon - Service de Néphrologie et Rhumatologie Pédiatriques - Hôpital Femme Mère Enfant | Bron |
Lead Sponsor | Collaborator |
---|---|
Hospices Civils de Lyon |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | 6 minutes walk test | Distance traveled (in meters) in 6 minutes | Month 0 | |
Primary | 6 minutes walk test | Distance traveled (in meters) in 6 minutes | Month 6 | |
Primary | 6 minutes walk test | Distance traveled (in meters) in 6 minutes | Month 12 | |
Secondary | Weight | weight in kilograms will be measured with a scale | Month 0 | |
Secondary | Weight | weight in kilograms will be measured with a scale | Month 6 | |
Secondary | Weight | weight in kilograms will be measured with a scale | Month 12 | |
Secondary | Height | Size in meter measured with a meter | Month 0 | |
Secondary | Height | Size in meter measured with a meter | Month 6 | |
Secondary | Height | Size in meter measured with a meter | Month 12 | |
Secondary | body mass index | calculated with weight and height | Month 0 | |
Secondary | body mass index | calculated with weight and height | Month 6 | |
Secondary | body mass index | calculated with weight and height | Month 12 | |
Secondary | blood pressure | measurement of blood pressure (cm Hg) | Month 0 | |
Secondary | blood pressure | measurement of blood pressure (cm Hg) | Month 6 | |
Secondary | blood pressure | measurement of blood pressure (cm Hg) | Month 12 | |
Secondary | phosphocalcic biologic parameters | Ionosodium (mmol/L) | Month 0 and Month 12 | |
Secondary | phosphocalcic biologic parameters | potassium (mmol/L) | Month 0 and Month 12 | |
Secondary | phosphocalcic biologic parameters | calcium (mmol/L) | Month 0 and Month 12 | |
Secondary | phosphocalcic biologic parameters | chlore (mmol/L) | Month 0 and Month 12 | |
Secondary | phosphocalcic biologic parameters | bicarbonates (mmol/L) | Month 0 and Month 12 | |
Secondary | phosphocalcic biologic parameters | glucose (mmol/L) | Month 0 and Month 12 | |
Secondary | phosphocalcic biologic parameters | urea (mmol/L) | Month 0 and Month 12 | |
Secondary | phosphocalcic biologic parameters | creatinemia (mmol/L) | Month 0 and Month 12 | |
Secondary | phosphocalcic biologic parameters | phosphorus (mmol/L) | Month 0 and Month 12 | |
Secondary | phosphocalcic biologic parameters | proteinemia (g/L) | Month 0 and Month 12 | |
Secondary | phosphocalcic biologic parameters | Vitamin D (nmol/L) | Month 0 and Month 12 | |
Secondary | phosphocalcic biologic parameters | 1-25 OH vitamin D (pmol/L) | Month 0 and Month 12 | |
Secondary | phosphocalcic biologic parameters | PTH (ng/L) | Month 0 and Month 12 | |
Secondary | phosphocalcic biologic parameters | alkaline bone phosphatases (U/L) | Month 0 and Month 12 | |
Secondary | phosphocalcic biologic parameters | CTX (pg/ml)crosslaps | Month 0 and Month 12 | |
Secondary | phosphocalcic biologic parameters | osteocalcin (µg/L) | Month 0 and Month 12 | |
Secondary | phosphocalcic biologic parameters | ferritin (µg/L) | Month 0 and Month 12 | |
Secondary | phosphocalcic biologic parameters | blood count formula : leucocytes (giga/L), erythrocytes (tera/L), hemoglobin (g/L), hematocrit (%), platelets (giga/L) | Month 0 and Month 12 | |
Secondary | phosphocalcic biologic parameters | calciuria (mmol/L) | Month 0 and Month 12 | |
Secondary | phosphocalcic biologic parameters | Ionosodium (mmol/L) potassium (mmol/L), calcium (mmol/L), chlore (mmol/L), bicarbonates (mmol/L), glucose (mmol/L), urea (mmol/L), creatinemia (mmol/L), phosphorus (mmol/L), proteinemia (g/L), Vitamin D (nmol/L), 1-25 OH vitamin D (pmol/L), PTH (ng/L), alkaline bone phosphatases (U/L), CTX (pg/ml)crosslaps, osteocalcin (µg/L), NFS, ferritin (µg/L), blood count formula : leucocytes (giga/L), erythrocytes (tera/L), hemoglobin (g/L), hematocrit (%), platelets (giga/L), calciuria (mmol/L), urinary creatinin (mmol/L). | Month 0 and Month 12 | |
Secondary | ration lean mass / fat mass | Dual-energy X-ray absorptiometry (DXA) | Month 0 | |
Secondary | ration lean mass / fat mass | Dual-energy X-ray absorptiometry (DXA) | Month 12 | |
Secondary | Respiratory Functional Exploration | Month 0 | ||
Secondary | Respiratory Functional Exploration | Month 12 | ||
Secondary | Thickness intima / media | echography | Month 0 | |
Secondary | Parameters of the connected watch : number of steps | data recovery of the connected watch | Month 0 and Month 6 and Month 12 | |
Secondary | Parameters of the connected watch : distance traveled | data recovery of the connected watch | Month 0 and Month 6 and Month 12 | |
Secondary | Parameters of the connected watch : calories consumption | data recovery of the connected watch | Month 0 and Month 6 and Month 12 | |
Secondary | Ratio thickness intima / media | echography | Month 12 | |
Secondary | Bone mineral density | Dual-energy X-ray absorptiometry (DXA) | Month 0 | |
Secondary | Bone mineral density | Dual-energy X-ray absorptiometry (DXA) | Month 12 | |
Secondary | Number of new fractures | Month 1 | ||
Secondary | Number of new fractures | Month 3 | ||
Secondary | Number of new fractures | Month 6 | ||
Secondary | Number of new fractures | Month 9 | ||
Secondary | Number of new fractures | Month 12 | ||
Secondary | Quality of life questionnaire : PedsQL | Measurement Model for the Pedratric Quality of Life Inventory
The 4 Multidimensional Scales and 3 Summary Scores are Scales Physical Functioning (8 items) Emotional Functioning (5 items) Social Functioning (5 items) School Functioning (5 items) Summary Scores Total Scale Score (23 items) Physical Health Summary Score (8 items) Psychosocial Health Summary Score (15 items) |
Month 0 | |
Secondary | Quality of life questionnaire : PedsQL | Measurement Model for the Pedratric Quality of Life Inventory
The 4 Multidimensional Scales and 3 Summary Scores are Scales Physical Functioning (8 items) Emotional Functioning (5 items) Social Functioning (5 items) School Functioning (5 items) Summary Scores Total Scale Score (23 items) Physical Health Summary Score (8 items) Psychosocial Health Summary Score (15 items) |
Month 6 | |
Secondary | Quality of life questionnaire : PedsQL | Measurement Model for the Pedratric Quality of Life Inventory
The 4 Multidimensional Scales and 3 Summary Scores are Scales Physical Functioning (8 items) Emotional Functioning (5 items) Social Functioning (5 items) School Functioning (5 items) Summary Scores Total Scale Score (23 items) Physical Health Summary Score (8 items) Psychosocial Health Summary Score (15 items) |
Month 12 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03557567 -
NGS Strategy Effectiveness in Molecular Diagnosis
|
||
Not yet recruiting |
NCT05559801 -
Mesenchymal Cell Therapy in Osteogenesis Imperfecta (OI)
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT02531087 -
Urinary Biomarkers of OI Pathobiology
|
||
Completed |
NCT01713231 -
Effect of High-Dose Vitamin D on Bone Density in Osteogenesis Imperfecta
|
Phase 4 | |
Completed |
NCT00655681 -
Prevention of Post Operative Bone Loss in Children
|
N/A | |
Recruiting |
NCT06065111 -
Study of Osteogenesis Imperfecta Tendon
|
||
Withdrawn |
NCT03216486 -
An Exploratory Study of BPS804 Treatment in Adult Patients With Type I, III or IV Osteogenesis Imperfecta
|
Phase 2 | |
Recruiting |
NCT06086613 -
A First-in-Human Study Evaluating AGA2115 in Adult Healthy Volunteers
|
Phase 1 | |
Completed |
NCT04009733 -
Epigenetic Regulation of Osteogenesis Imperfecta Severity : miROI Study
|
N/A | |
Completed |
NCT04231916 -
High Resolution Thermal Imaging to Identify Vertebral Fractures in Children and Young People With Osteogenesis Imperfecta
|
N/A | |
Active, not recruiting |
NCT02814591 -
Development of a Non-invasive Assessment of Human Bone Quality Using Spatially Offset Raman Spectroscopy
|
||
Completed |
NCT00982124 -
An Efficacy and Safety Trial of Intravenous Zoledronic Acid in Infants Less Than One Year of Age, With Severe Osteogenesis Imperfecta
|
Phase 3 | |
Completed |
NCT00001305 -
Growth Hormone Therapy in Osteogenesis Imperfecta
|
Phase 3 | |
Terminated |
NCT01679080 -
The Effect of Treatment With Teriparatide and Zoledronic Acid in Patients With Osteogenesis Imperfecta
|
Phase 2 | |
Completed |
NCT00106028 -
Safety and Efficacy of Risedronate in the Treatment of Osteogenesis Imperfecta in Children
|
Phase 3 | |
Recruiting |
NCT04152551 -
Effects of Bisphosphonates on OI-Related Hearing Loss
|
Phase 4 | |
Completed |
NCT00705120 -
Treatment of Severe Osteogenesis Imperfecta by Allogeneic Bone Marrow Transplantation
|
Phase 1 | |
Recruiting |
NCT04169568 -
Osteogenesis Imperfecta Blood Pressure Study
|
||
Completed |
NCT03064074 -
Safety of Fresolimumab in the Treatment of Osteogenesis Imperfecta
|
Phase 1 | |
Not yet recruiting |
NCT05258019 -
Site Preservation After Tooth Extraction
|